Analyst Ratings for bluebird bio (BLUE) [Neutrals]
BLUE Rating Summary
BLUE Price Target Summary
- Highest: $36.50 (BofA Securities)
- Lowest: $1.00 (Goldman Sachs)
- Average: $8.02
* Over Last 12-Mos
Overall Rating:
NEUTRAL
Rating Trend:
Avg. $ Target:
$8.02 (+791.4%)
* Over Last 12-Mos
Rating Score: 4.2 / 10
Percentile Rank: 42%
Avg. $ Target:
$8.02 (+791.4%)
* Over Last 12-Mos
Rating Score: 4.2 / 10
Percentile Rank: 42%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 12/8/2023 | Morgan Stanley | Jeffrey Hung | Upgrade | Equalweight (Underweight) |
7.00 (3.00) |
4.83 (0.90) |
-81.37% | Details |
| 10/17/2023 | Cantor Fitzgerald | Eric Schmidt | New Coverage | Neutral (N/A) |
N/A (N/A) |
2.80 (0.90) |
-67.86% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
